

Tabituximab barzuxetan (exclude Y90)

| | |
|-----------|---|
| Cat. No.: | HY-P99581 |
| CAS No.: | 1612758-88-9 |
| Target: | Wnt |
| Pathway: | Stem Cell/Wnt |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

Description

Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research^[1].

REFERENCES

[1]. Anne-Laure Giraudet, et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA